|
Video: What is a Stock Split?
|
|
Monte Rosa Therapeutics is a biopharmaceutical company. Co. has developed a protein degradation platform, called QuEEN (Quantitative and Engineered Elimination of Neosubstrates), to enable its target-centric approach to its molecular glue degraders (MGDs) discovery and development. Co.'s QuEEN platform enables it to identify protein targets and associated MGD product candidates that are designed to eliminate therapeutically-relevant proteins. Co.'s primary candidate, MRT-2359, is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers overexpressing one of the Myc family genes (c-Myc, N-Myc and L-Myc). According to our GLUE split history records, Monte Rosa Therapeutics has had 0 splits. | |
|
Monte Rosa Therapeutics (GLUE) has 0 splits in our GLUE split history database.
Looking at the GLUE split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Monte Rosa Therapeutics shares, starting with a $10,000 purchase of GLUE, presented on a split-history-adjusted basis factoring in the complete GLUE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/25/2021 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$18.86 |
|
End price/share: |
$7.05 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-62.62% |
|
Average Annual Total Return: |
-30.00% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$3,738.01 |
|
Years: |
2.76 |
|
|
|
|
|